Share Prices & Company Research

Stockbroking

Astrazeneca Plc

Current Price 11228.00p Bid 11172.00p Ask 11274.00p Change 1.89%
Last Updated: 19/08/2022 23:40. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2021

Revenue
£37.42m
Operating Profit/Loss
£1.06m
Dividend yield (%)
2.80
Total dividend for year
$n/a
Dividend cover
0.03
P/E Ratio
1279.80

Key Personnel

Mr Pascal Soriot
CEO and Executive director
Dr Aradhana Sarin
CFO & Executive Director
Mr Leif Johansson
Non-Executive Chairman
Dr Euan Ashley
Non-Executive Director
Mr Andreas Rummelt
Non-Executive Director
Mr Marcus Wallenberg
Non-Executive Director
Mr Michel Demare
Non-Executive Director
Mr Philip A J Broadley
Non-Executive Director
Mr Tony Mok
Non-Executive Director
Mrs Deborah DiSanzo
Non-Executive Director
Mrs Nazneen Rahman
Non-Executive Director
Mrs Sheri McCoy
Non-Executive Director
Ms Diana Layfield
Non-Executive Director

Stock Details

EPIC
AZNL
ISIN
GB0009895292
Shares in Issue
1,264.16m
Market cap
£141,940.19m

Analyst Views (7)

Strong Buy
 
0%
Buy
 
100.00%
Hold
 
0%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
11,228.00p
Bid Price
11,172.00p
Ask Price
11,274.00p
Volume
362,785
Change Today
208.00p
% Change Today
1.89%
Open
11,002.00p
Previous Close
11,228.00p
Intraday High
11,292.00p
Intraday Low
10,984.00p
52 Week High
11,292.00p
52 Week Low
8,038.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

AstraZeneca's prostate cancer drug gets US priority review 16/08/2022 08:07:24 AstraZeneca breast cancer drug meets primary and secondary endpoints in new trial 15/08/2022 07:27:01 AstraZeneca, Daiichi's Enhurtu gets US approval to treat lung cancer 12/08/2022 07:04:40 AstraZeneca gets US approval for breast cancer treatment 08/08/2022 09:49:34 AstraZeneca breast cancer drug receives EU approval 04/08/2022 08:52:15 ShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline 29/07/2022 12:45:53 AstraZeneca raises FY revenue guidance, names new chairman 29/07/2022 07:07:44 Friday preview: US inflation data, AstraZeneca in the spotlight 28/07/2022 12:22:25 AstraZeneca GMG drug recommended for EU approval 25/07/2022 07:56:38 AstraZeneca asthma drug gets EU marketing approval 25/07/2022 07:43:35 AstraZeneca breast cancer drug granted priority review by US FDA 25/07/2022 07:12:30 AstraZeneca breast cancer drug granted priority review by US FDA 25/07/2022 07:12:30 AstraZeneca's HER2-positive breast cancer drug receives EU approval 19/07/2022 07:02:00 AstraZeneca agrees to acquire TeneoTwo 05/07/2022 07:04:44 Covid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants 01/07/2022 13:22:58 Oxford Biomedica signs new Covid vaccine deal with AstraZeneca 01/07/2022 07:03:02 AstraZeneca receives positive interim results from lung cancer drug trial 30/06/2022 07:13:50 AstraZeneca's breast cancer drug recommended for EU marketing authorisation 27/06/2022 07:04:08 Citi reiterates 'buy' on AstraZeneca on the back of trial results for Enhertu against breast cancer 22/06/2022 10:06:38 AstraZeneca receives 'positive' results from Phase III trial on eplontersen 21/06/2022 08:13:33 Berenberg stays at 'buy' for AstraZeneca after trial results for Enhertu against breast cancer 06/06/2022 17:48:52 AstraZeneca-Daiichi's Enhertu reports positive survival rate results 06/06/2022 07:47:09 AstraZeneca autoimmune treatment meets trial endpoint 05/05/2022 08:42:16 AstraZeneca's Imfinzi granted priority review in the US 04/05/2022 07:42:01 AstraZeneca reiterates guidance after first quarter growth 29/04/2022 08:23:57

Income Statement

Year End Date
31 Dec 2021
31 Dec 2020
 
$ (M)
$ (M)
Continuing Operations
Revenue
37.42
26.62
Operating Profit/Loss
1.06
5.16
Net Interest
-1.26
-1.22
Pre-Tax Profit
-0.27
3.92
Profit After Tax from continuing operations
0.12
3.14
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
0.12
3.14
Attributable to:
Equity Holders of Parent Company
0.11
3.20
Minority Interests
n/a
-52.00
Total Dividend Paid
$n/a
$n/a
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2021
31 Dec 2020
Basic
8.00c
244.00c
Diluted
8.00c
244.00c
Adjusted
8.00c
244.00c
Dividend per Share
$n/a
$n/a

Assets

Year End Date
31 Dec 2021
31 Dec 2020
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
10,171.00
8,917.00
Intangible Assets
62,384.00
32,792.00
Investment Properties
n/a
n/a
Investments
1,237.00
1,147.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
5,327.00
4,329.00
Current Assets
Inventories
8,983.00
4,024.00
Trade & Other Receivables
9,644.00
7,022.00
Cash at Bank & In Hand
6,329.00
7,832.00
Current Asset Investments
n/a
160.00
Other Current Assets
1,288.00
666.00
Other Assets
n/a
n/a
Total Assets
105,363.00
66,729.00

Liabilities

Year End Date
31 Dec 2021
31 Dec 2020
 
$ (M)
$ (M)
Current Liabilities
Borrowings
1,893.00
2,386.00
Other Current Liabilities
20,701.00
17,921.00
Total Current Liabilities
22,594.00
20,307.00
Non-Current Liabilities
Borrowings
28,888.00
17,994.00
Provisions
7,162.00
3,502.00
Other Non-Current Liabilities
7,432.00
9,288.00
Total Non-Current Liabilities
43,482.00
30,784.00
Other Liabilities
n/a
n/a
Total Liabilities
66,076.00
51,091.00

Net Assets

Year End Date
31 Dec 2021
31 Dec 2020
 
$ (M)
$ (M)
Net Assets
39,287.00
15,638.00

Capital & Reserves

Year End Date
31 Dec 2021
31 Dec 2020
 
$ (M)
$ (M)
Share Capital
387.00
328.00
Share Premium Account
35,126.00
7,971.00
Other Reserves
2,045.00
2,024.00
Retained Earnings
1,710.00
5,299.00
Shareholders Funds
39,268.00
15,622.00
Minority Interests/Other Equity
19.00
16.00
Total Equity
39,287.00
15,638.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
1st Interim
11 Aug 2022
12 Sep 2022
93.00¢
2nd Interim
24 Feb 2022
28 Mar 2022
197.00¢
1st Interim
12 Aug 2021
13 Sep 2021
90.00¢
2nd Interim
25 Feb 2021
29 Mar 2021
190.00¢
1st Interim
13 Aug 2020
14 Sep 2020
90.00¢
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2021
31 Dec 2020
Dividend growth
2.50%
n/a%
Dividend yield
2.80%
3.20%
Dividend cover
0.03
0.87


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.